Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation. - Wikidata - awgldk - TriplyDB

Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

http://www.wikidata.org/entity/Q37793222

about

Virus-specific T-cell therapy in solid organ transplantation.Colonic EBV-Associated Lymphoproliferative Disorder in a Patient Treated with Rabbit Antithymocyte Globulin for Aplastic Anemia.Epstein-Barr virus-associated lymphoproliferative disorder developed following autologous peripheral blood stem cell transplantation for relapsing Hodgkin's lymphoma.Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases.Mature T/NK-cell lymphoproliferative disease and Epstein-Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate.

P2860

Q38568902-A48EE237-E8C6-4581-A2EA-91DA3C7597A0 Q41814460-72523471-12D7-4A63-96A9-99F1EDE31173 Q42131229-7CE8CB34-0296-4BDD-AEA0-28B14CD0B444 Q42264347-DB91E139-41A0-4862-9A31-FCC61D2EDD21 Q45352184-037BD018-76E2-4F41-9760-D3D0228461E5

P2860

Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

http://www.wikidata.org/entity/Q37793222

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Immunotherapeutic options for ...... ase following transplantation.

@en

Immunotherapeutic options for ...... ase following transplantation.

@nl

type

label

Immunotherapeutic options for ...... ase following transplantation.

@en

Immunotherapeutic options for ...... ase following transplantation.

@nl

prefLabel

Immunotherapeutic options for ...... ase following transplantation.

@en

Immunotherapeutic options for ...... ase following transplantation.

@nl

P1433

Q37793222-1F3E9B54-89F0-4339-B996-DDA056BB215E

P1476

Q37793222-069DAEDA-7BF3-4AAC-BDCD-DE832DB45E9B

P2093

Q37793222-1F4D74A0-65FA-4AB1-935C-9130086A8ADC

Q37793222-61D06B1A-D4A0-4919-B44C-60BF045AA635

Q37793222-69EE9B42-40BA-4DC5-9044-50D5AA553092

P2860

Q37793222-0601D35D-0229-429B-90A7-C6F788C17383

Q37793222-0774FA42-1551-4B2F-A14F-97FBAC1F1813

Q37793222-0D76E50C-8236-4FAB-B4E4-7014D5358398

Q37793222-0E74CDE8-4878-44CC-BE7F-490DB25A9047

Q37793222-10157386-218C-4A61-9894-4F7A213EFB5A

Q37793222-12DCCA86-30E6-438D-B0AF-BACCDB5AA675

Q37793222-16A9E263-5471-4BC4-8907-2430300D3C7C

Q37793222-1778CAA0-8304-41C6-A9A5-BFA2D4DD9028

Q37793222-1DA52417-8137-419A-9363-B46E82E3D8CA

Q37793222-1DADD130-72C2-4B36-BA61-E41466A1D8B9

P304

Q37793222-89C86C10-1364-4F9E-A63C-8C47DE1B2EC2

P31

Q37793222-8F743B99-8011-4635-8B59-4D8CA4424DC1

P356

Q37793222-58A38FAA-05A5-42C5-8990-66DC8A7344AA

P433

Q37793222-25369E69-65B7-4249-8612-3E8759822E56

P478

Q37793222-4763B896-0E4F-4971-9873-5F8C2248BBDC

P577

Q37793222-AD8200B2-D298-4021-B509-D353310CAD55

P5875

Q37793222-2F19678B-AA2D-4645-925C-AD4C0E4B01A9

P698

Q37793222-2A4E1065-D392-4283-927E-9D84CC1D5D08

P921

Q37793222-51AF7F19-7242-4B35-BCDE-4B333174E831

Q37793222-D8B6375B-DC49-4DC9-ACD4-E279966575A3

P932

Q37793222-C7283090-94A4-4E43-A4E5-F4F340D8C568

P356

P1433

P1476

Immunotherapeutic options for ...... ase following transplantation.

@en

P2093

Cliona M Rooney

http://www.w3.org/2001/XMLSchema#string

Donald R Shaffer

http://www.w3.org/2001/XMLSchema#string

Stephen Gottschalk

http://www.w3.org/2001/XMLSchema#string

P2860

Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.

Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.

Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder.

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.

Malignant lymphomas in transplantation patients.

P304

663-671

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT.10.43

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46577032

http://www.w3.org/2001/XMLSchema#string

P698

20874650

http://www.w3.org/2001/XMLSchema#string

P921

Epstein–Barr virus

P932

3075565

http://www.w3.org/2001/XMLSchema#string